Obesity journal commentary asks whether multi-dose tirzepatide pens will drive microdosing
A new commentary says multi-dose tirzepatide pens make off-label dose splitting easier, while the dosing and safety evidence patients would need is still missing [1][2].
A commentary in the journal Obesity asks whether the arrival of multi-dose tirzepatide pens will make microdosing — using a fraction of a standard dose by splitting one pen — more common, and argues the missing evidence on the practice has moved from an academic question to an urgent one [1]. The article is titled "Micro Doses, Macro Potential? Considerations for Microdosing Tirzepatide in Multi-Dose Pens" [1]. Tirzepatide is sold as Mounjaro and Zepbound. The same case was made for semaglutide multidose pens in Diabetes Care in 2025 [2].
The Diabetes Care article was published online January 14, 2025, and in the March 2025 issue, volume 48, issue 3, pages e25–e27 [2]. It was written by pharmacists and physicians at UNC Health and the University of North Carolina School of Medicine [2]. The authors describe microdosing as "an alternative strategy that allows for fractional doses" and write that while it is "unconventional," it "offers a tailored solution to maximize therapeutic benefit, minimize adverse effects, and address availability concerns" [2].
That article lists situations where it says fractional dosing may help: switching from one GLP-1 drug to another, stepping a dose up or down, managing severe gastrointestinal side effects, and stretching a pen for people paying cash when insurance will not cover the drug [2]. It notes that shortages and cost barriers have led some patients to buy unregulated versions of GLP-1 drugs, and it presents continued use of approved products through microdosing as a safer alternative [2].
The semaglutide article gives specific mechanics. Each semaglutide multidose pen device delivers roughly 72 unnumbered "clicks" of medication, and the authors say clinicians should teach patients to use the pen dosing window to count and administer a specific number of clicks for an individualized dose, using written instructions and demonstration devices [2]. The beyond-use date for that pen is 56 days at room temperature or refrigerated, after which any remaining medication should be discarded according to package labeling [2]. Only four to six pen needles come with each original package, so the authors recommend additional 32-gauge pen needles [2].
Comparable click-level or device-level detail for tirzepatide multi-dose pens has not been reported [1]. How many patients microdose tirzepatide, what doses they use, and how the practice affects weight, blood sugar, or side effects has not been disclosed [1].
Why it matters for patients
Microdosing is not one of the dosing schedules in the approved labeling for these drugs, and the evidence gap that both articles describe is about what happens when patients use them that way anyway [1][2]. No trial has tested microdosed tirzepatide, and the new commentary argues that this gap can no longer be treated as academic now that the devices make splitting easier [1].
The practical details matter more than the debate framing. Fractional dosing depends on counting clicks on a device whose approved doses are set amounts, and the Diabetes Care authors say both patients and providers need education on the technique, including written instructions and practice with demonstration devices [2]. The 56-day beyond-use date means a pen used at a fraction of its labeled dose still expires on the same schedule, so slower use can leave medication to discard [2]. For people paying out of pocket, the same authors argue that extending each pen can lower cost and improve access when insurance coverage is unavailable [2].
What is not established is whether smaller doses of tirzepatide produce the same benefits, fewer side effects, or different risks than standard doses. Neither commentary reports trial data, and no such results have been announced [1][2].
What happens next
The discussion has continued in the journals. A comment responding to the semaglutide article was later published in Diabetes Care, volume 48, issue 7, page e93 [2]. No clinical trial of microdosed tirzepatide has been registered or announced, and no timeline for one has been disclosed [1]. Whether drugmakers will add fractional-dose markings or instructions to multi-dose pens has not been reported [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.